Bystander effect tumoricidal therapy by expressing an HSV-tk gen

Details Bystander effect tumoricidal therapy by expressing an HSV-tk gen Bystander effect tumoricidal therapy by expressing an HSV-tk gen

1994-07-13

2000-04-04

Crouch, Deborah

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

424 932, 424 936, 4353201, A61K 4800, C12N 1500

Patent

active

060457899

ABSTRACT:
A method for treating an tumor involves the initial identification of the tumor as one displaying a "bystander effect," whereby in vivo transfer of a gene conferring sensitivity to chemotherapeutic agent affects both transformed and non-transformed tumor cells. Into a tumor thus characterized is introduced in situ a retroviral vector containing the sensitizing gene. The retroviral vector, which may replication-defective or replication-competent, can be introduced directly (if it is replication-competent) or can be provided by means of a packaging cell line. Treatment of the patient with the chemotherapeutic agent thereafter effects tumor regression when as few as 10% of tumor cells are transformed, while normal tissue is not damaged. The anti-tumor impact of the treatment can be increased when the transducing vector also encodes an immune response-enhance substance such as IL-2 or another cytokine.

REFERENCES:
patent: 5358866 (1994-10-01), Mullen et al.
patent: 5529774 (1996-06-01), Barba et al.
patent: 5601818 (1997-02-01), Freeman et al.
Moolten, 1990. Critical Reviews in Immunology. 10(3):203-233.
Gansbacher et al., Cancer Res. 50 (Dec. 15, 1990), pp. 7820-7825.
Tepper et al., Cell, vol. 57 (May 5, 1989), pp. 503-512.
Asher et al., J. Immunol. vol. 146, No. 9 (May 1, 1991) pp. 3227-3234.
Yannelli et al., J. Immunol., vol. 135, No. 2 (Aug. 1985) pp. 900-905.
St. Clair et al., Antimicrob. Ag. Chemother, vol. 31, No. 6 (Jun. 1987) pp. 844-849.
Fearon et al. Cell, vol. 60 (Feb. 9, 1990) pp. 397-403.
Gansbacher, J. Exp. Med. vol. 172 (Oct. 1990) pp. 1217-1224.
Moolten, Cancer Res. 46 (Oct. 1986) pp. 5276-5281.
Orkin & Motulsky, Dec. 7, 1995. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", National Institutes of Health, USA.

Affiliated with

Also associated with

Rating

Bystander effect tumoricidal therapy by expressing an HSV-tk gen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bystander effect tumoricidal therapy by expressing an HSV-tk gen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bystander effect tumoricidal therapy by expressing an HSV-tk gen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-362207